Home
overview

Join SAE’s 3rd annual Transdermal and Microneedle Drug Delivery conference – leading the transition of drug delivery beyond the needle.
 

Collaborate across a high-level 2-day programme.


Collaborate with forward-thinking drug development and delivery experts to discuss case studies and real-world examples of delivery R&D, vaccine application, and diversifying capabilities.


 

Transdermal and Microneedle Array Patches (MAPs) are one of the exciting fields and fast-growing in pharmaceutical development. Offering a combination of unrivalled potency – from increased community access, to consistent long-term delivery and diagnostic capabilities – this technology is at the vanguard of increasing efficacy and global access to transformative products.
 

Highlights include:

  • Successes in clinical data and vaccine delivery 
  • Innovative capabilities and applications of transdermal and microneedle patches
  • Manufacturing challenges and progress
  • Insights and Q&A opportunities with key regulators

Engage with senior industry developers regarding their real-life experiences and case-studies for both drug and platform development.

Gain insights with key industry experts and opinion leaders regarding the increasingly wide and smart capabilities of transdermal and microneedle array patches.

Understand how to optimise design and manufacturing to achieve your technological requirements at necessary value and scale

Interact with national and global regulatory bodies to smooth the remaining steps to full regulatory approval

Collaborate with transnational organisations to forge cooperative solutions to the industry’s outstanding challenges
 

Connect with those who are shaping the future of drug delivery. 

Pharmaceutical Companies
Benchmark against the latest innovations driving transdermal and microneedle technology forward for vaccine and therapeutic pipelines. Previous participants include:

  • AbbVie
  • Bayer AG
  • GSK
  • Merck
  • Vaxxas
  • Vaxess Technologies
     

 

Transdermal and MAPs Manufacturers
Network with the leading pharma and biotech organisations looking to develop their pipelines for transdermal and microneedle delivery. Previous participants include:

  • Harro Höfliger Verpackungsmaschinen GmbH
  • LTS Lohmann Therapie-Systeme AG
  • QuadMedicne, Inc.
  • Raphas
  • Raumedic UK Ltd
     

Global Opinion Leaders and Global Accelerators
Previous participants include:

  • Bill and Melinda Gates Foundation
  • Gavi, The Vaccine Alliance
  • PATH
  • University of Cardiff
  • University of Swansea
  • Queen’s University Belfast
  • World Health Organisation
     

4P Therapeutics; AbbVie; Anodyne Nanotech, Inc; ASPR/BARDA; AstraZeneca; Bayer AG; Bill & Melinda Gates Foundation; BiondVax Pharmaceuticals Ltd; Cardiff University; Emergex USA Corporation ; Emergex Vaccines; GSK Vaccines; GVGH; Harro Höfliger; Harro Hofliger Verpackungsmaschinen GmbH; HTL; Imperial BioScience; Juvic; Kookmin University; Medherant Limited; Merck; Micron Biomedical; Nutriband Inc; QuadMedicine, Inc.; Queen's University Belfast; Raphas; Raumedic UK Ltd; Silex Pharmaceuticals; Starton Therapeutics; Swansea University; Vaxess Technologies ; Vaxxas; Vaxxas Inc; Verndari ; World Health Organization;

Conference agenda

clock

8:00

Registration & Coffee

clock

9:00

Chair's Opening Remarks

Dr Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University

clock

9:10

Leading Clinical Data, Information, and Results and Updates

Steven Damon, CEO, Micron Biomedical

  • Clinical stage dissolving microneedle patch for MR vaccine
  • Assing results of three clinical trials
  • Steps to commercialise MAP technology
  • clock

    9:50

    Steps Forward to Fully Establish the Advantages of MAPs

    Dr Simona Gallorini, Expert Scientist in Advanced Technologies, Technical Research and Development - Drug Development, , GSK

  • Current challenges and concerns of industry
  • Encouragement from current trials and clinical data
  • Assessing industry barriers to entry and key requirements for increased industry uptake
  • Optimising MAP devices for vaccine R&D pipelines
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Non-invasive Transdermal Drug Delivery of Peptides and Proteins

    Expanding the window of transdermal opportunity: delivery of larger molecules like Semaglutide and Insulin
    Update of pre-clinical results

    Dr Pawel Biernat, Chief Technology Officer and Co-Founder, Biotts

    Aleksandra Puton, Business Partner, Biotts

    clock

    11:40

    Applying the Biomedical Catalyst 2023 Grant to Further Develop Microneedle Patch Technology (MPT)

    Dr Muhammet Avcil, Managing Director, Imperial BioScience

  • Assessing the key advantages of ‘dissolving microstructure’ MPTs
  • Applying cutting-edge technology to transition into clinical stage in the development of MPT medicinal products
  • Reviewing the application of MPT technology to both therapeutic and cosmetic purposes
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Transforming Therapeutics through Transdermal Delivery: Accelerating and Innovating Treatments

    Dr Niraj Vasisht

    Dr Niraj Vasisht, Chief Technology Officer, Corium International

  • Clinical development and gaining regulatory approval for the Adlarity patch
  • Innovative solutions in our Corplex® transdermal platform
  • Applying intradermal delivery to new molecules and body systems
  • clock

    14:00

    Closing the Chapter: Reflecting on Zosano’s Legacy

    Dr Mahmoud Ameri, VP, Emergex USA Corporation

  • Industry Leadership: Zosano played a pivotal role in shaping the industry landscape and infl uencing competitors
  • Innovation and pioneering: increasing the delivered dose from mg to mg
  • Core values: A culture of continuous innovation, encouraging employees to think creatively and take calculated risks
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    De-risking Development of Transdermal and Microneedle Drug and Vaccine Delivery Technologies

    Tanima Sinha, Interdisciplinary Scientist Vaccines Branch, Influenza and Emerging Infectious Diseases Division, Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness & Response (ASPR), US Department of Health and Human Services

  • Continued challenges with MAP development
  • Adjuvants for MAP vaccine products
  • Regulatory considerations
  • clock

    15:50

    Academic Panel: Applying Lessons from Vaccination Progress to the Next Generation of Transdermal and Microneedle Delivery

  • Drawing lessons from progress in vaccination trials and development
  • Overviewing key academic avenues of research - expanding the boundaries of drug delivery
  • Commercialising academic progress
  • Dr Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University

    Professor James Birchall, eputy Head, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences , Cardiff University

    Dr Nuria Puigmal Dominguez, Blavatnik Fellow, Harvard Business School

    Dr Waleed Faisal, Project Manager, School of Pharmacy, University College Cork

    clock

    16:30

    Chair’s Closing Remarks and Close of Day One

    Dr Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chair's Opening Remarks

    Michael Schrader, Co-Founder & CEO, Vaxess Technologies

    clock

    9:10

    MIMIX: Clinical Proof of Concept of the Transformational Power of Self-Delivery through Patches

    Michael Schrader, Co-Founder & CEO, Vaxess Technologies

  • Updates on clinical progress with the MIMIX dissolving, sustained-release microarray patch platform
  • Updates on additional pipeline programs on the MIMIX platform
  • clock

    9:50

    Microarray Patches: Opportunities for Global Health Impact and Health Equity

    Courtney Jarrahian, Program Leader, Packaging and Delivery Technologies, PATH

  • Priorities for public health impact with microarray patches
  • VIPS Alliance activities to accelerate vaccine microarray patches for global health
  • Using human factors evaluations and stakeholder consultations to identify product attributes for program impact
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Achieving Breakthroughs in Vaccines for LMIC communities through MAPS: Results of a Measles and Rubella Microneedle Patch Phase 1/2 Clinical Trial

    Senior Representative

    Senior Representative, Medical Research Council Unit in The Gambia (MRCG), London School of Hygiene and Tropical Medicine (LSHTM)

  • Demonstrating the potential of MAPs to deliver vaccines to children safely
  • Technical considerations for microneedle vaccine and dosage
  • Patient and parent acceptability
  • Phase 1/2 clinical trial updates
  • clock

    11:40

    Joint Session: Creating MAPs for use in Low- and Middle-Income Countries (LMICs)

  • How to create MAPs suitable for use in LMICs
  • Scaling up MAP manufacturing: Challenges and successes
  • What other antigens should be pursued after Measles-Rubella (MR) MAPS?
  • Steven Damon, CEO, Micron Biomedical

    Dr Ajoy Chakrabarti, Portfolio & Platform Lead, Polio, Bill & Melinda Gates Foundation

    David Hooey

    David Hooey, CEO, Vaxxas

    clock

    12:20

    Networking Lunch

    clock

    13:20

    The Role of Vaccine Microarray Patches in CEPI’s 100-Days Mission

    Dr Renske Hesselink, CMC Technology Lead, CEPI

  • Vaccine Microarray Patches (MAPs) and other needle-free delivery technologies can make vaccines more equitably accessible in epidemic and pandemic response situations 
  • Platform technology development is critical for preparedness
  • Speed of development as well as scalability of manufacturing are key to rapid response and equitable access
  • clock

    14:00

    Progressing Next-Generation Vaccines using Hollow Microneedle Delivery – Results from the Emergex Vaccines naNO-Dengue and naNO-COVID Phase I Clinical Trial

    Dr Brian Pfister, Vice President, Emergex USA Corporation

  • Demonstrating successful coating and stability of COVID-19 vaccine on MNP
  • Positive Phase 1 data of DengueTcP treatment
  • Novel proprietary MNP delivery platform
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Achieving Next Generation Needle-Free Vaccine Administration

    Tom Lake, Senior Vice President, Strategic Alliances and Commercialization, Vaxxas

  • Maturing HD-MAP technology for vaccine administration
  • Analysing results from recent usability and accessibility studies
  • Evaluating the potential of needle-free vaccine delivery
  • clock

    15:50

    Industry Panel: Approaching and Resolving Practical and Logistical Challenges in Microneedle Delivery Maturation

  • Universal challenges when commercialising research
  • Drawing lessons from previous successes and failures
  • Achieving cost-effective manufacturing at scale
  • Steven Damon, CEO, Micron Biomedical

    Dr Ajoy Chakrabarti, Portfolio & Platform Lead, Polio, Bill & Melinda Gates Foundation

    Michael Schrader, Co-Founder & CEO, Vaxess Technologies

    clock

    16:30

    Chair’s Closing Remarks and Close of Day Two

    Michael Schrader, Co-Founder & CEO, Vaxess Technologies


    Business Partner
    Biotts
    Program Leader, Packaging and Delivery Technologies
    PATH
    CEO
    Vaxxas
    Portfolio & Platform Lead, Polio
    Bill & Melinda Gates Foundation
    Vice President
    Emergex USA Corporation
    VP
    Emergex USA Corporation
    Managing Director
    Imperial BioScience
    Chief Technology Officer
    Corium International
    Blavatnik Fellow
    Harvard Business School
    Chief Technology Officer and Co-Founder
    Biotts
    CMC Technology Lead
    CEPI
    Senior Lecturer in Medical Engineering
    Swansea University
    Expert Scientist in Advanced Technologies, Technical Research and Development - Drug Development,
    GSK
    Project Manager, School of Pharmacy
    University College Cork
    Co-Founder & CEO
    Vaxess Technologies
    eputy Head, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences
    Cardiff University
    Medical Research Council Unit in The Gambia (MRCG)
    London School of Hygiene and Tropical Medicine (LSHTM)
    CEO
    Micron Biomedical
    Interdisciplinary Scientist Vaccines Branch, Influenza and Emerging Infectious Diseases Division, Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness & Response (ASPR)
    US Department of Health and Human Services
    Senior Vice President, Strategic Alliances and Commercialization
    Vaxxas
    Project Manager
    University College Cork

    VENUE

    Hilton London Kensington

    179-199 Holland Park Avenue, London, United Kingdom

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”
    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out